# Health-Miumiu(Hangzhou) Medicine Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/health-miumiu-hangzhou-medicine-co

- Industry: Healthcare Specialists
- Headquarters: Hangzhou, China
- Website: www.mmm920.com
- Total disclosed funding: $29M
- Latest round: Series B (Jun 19, 2024)
- Investors on record: 5

## About

Established in 2014 and based in Hangzhou, China, Health-Miumiu(Hangzhou) Medicine Co.,LTD is a medical drugs and materials procurement company that focuses on the sales of dental consumables and related products. It has 6 logistics centers, with 4 branch offices in Guangdong, Zhejiang, and Sichuan. Xiaoping Lin, the executive director and general manager of the company, is also the executive director of Hansfive (Hangzhou) Medical Technology. The company acquired certifications such as the quality management standardization of pharmaceutical experience. In August 2017, the company launched a dental medical products e-commerce platform. In June 2024, it raised approximately CNY 100 million in series B funding.

Health-Miumiu(Hangzhou) Medicine Co.,LTD's main businesses include the operation of a comprehensive dental platform, the development of dental digital systems, and the customization of dental products Its platform provides dental pulp medical equipment, orthodontic implant equipment, dental books, teeth whitening materials, etc., which cover DMG, LONGLY, KULZER, and other brands. It also provides denture care, equipment maintenance, and other denture services. The company also launched dental digital systems and customization services that combine intelligent data collection, digital medical design, and custom intelligence.

The company generates revenue by providing dental-related solutions.

The company will use the series B funding to upgrade the information technology of the integrated dental platform and improve customized services. The company will expand its digital product development, data services, medical services, supply chain services, value-added services, and other modules centered on the DaaS system.

## Funding rounds

- Series B, Jun 19, 2024, $14M — Xiaoka Capital, Blue Bay Capital, Korea Investment Partners (China), Shanghai INT Medical Instruments
- Series A, Oct 13, 2021, $16M — Korea Investment Partners (China), Jacobson Pharma Corporation Limited

## Investors

- Korea Investment Partners (China) (https://capitalatlas.ai/funds/korea-investment-partners-china) — Series A, Series B
- Jacobson Pharma Corporation Limited — Series A
- Xiaoka Capital (https://capitalatlas.ai/funds/xiaoka-capital) — Series B
- Blue Bay Capital — Series B
- Shanghai INT Medical Instruments — Series B